Not strictly stem-cell news, but pertinent. There has been a distinct lack of M&A activity in the biotech market this year.
Amgen won the bidding to takeover Horizons Therapeutics (not Bio Horizons) in what is the biggest biotech takeover this year:
"The $27.8 billion deal is by far the largest biotech acquisition of a year that has seen less M&A activity than many investors had anticipated."
https://www.barrons.com/articles/amgen-horizon-therapeutics-acquisition-stock-price-51670843416
At the risk of loathing, I should mention J&J (and Sanofi) were in the running too. Given J&J didn't buy Horizons, they might now be able to afford to buy Orthocell (that was a joke).
Stem Cell Therapy advancements, page-353
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $77.54M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 36.5¢ | $8.369K | 22.75K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 120364 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 5620 | 2 |
View Market Depth
| Last trade - 11.07am 20/08/2024 (20 minute delay) ? |
| OCC (ASX) Chart |